You are here: Home: BCU 2 | 2006: Kathleen I Pritchard, MD: Select Publications


Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data. Clin Cancer Res 2006;12(3 Pt 2):1037-48. Abstract

Gltick S. Changing the gold standard in adjuvant therapy for breast cancer: From tamoxifen to aromatase inhibition. Biomed Pharmacother 2005;59(Suppl 2):321-2. Abstract

Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005a;Abstract 16.

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005b;97(17):1262-71. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Ingle JN et al. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. San Antonio Breast Cancer Symposium 2005;Abstract 17.

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

Koberle D, Thürlimann B. Adjuvant endocrine therapy in postmenopausal breast cancer patients. Breast 2005;14(6):446-51. Abstract

Piccart-Gebhart MJ. Treatment guidelines for systemic adjuvant therapy of breast cancer: strengths and weaknesses. San Antonio Breast Cancer Symposium 2005;Abstract P1.

Saphner T et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46. Abstract

Thürlimann B et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract

Home · Search

Terms and Conditions of Use and General Disclaimer
Copyright © 2006 Research To Practice. All Rights Reserved